Preclinical Imaging Services EMIT Imaging offers Cryo-Fluorescence Tomography (CFT) services globally and also sells the Xerra preclinical imaging system. This combination enables cross-sell opportunities with pharma/biotech R&D teams and CROs seeking advanced biodistribution, whole-body imaging, and multi-plex co-localization capabilities. Sales actions: promote bundled CFT services with instrument access and offer pilot studies to demonstrate CFT advantages in drug delivery and target identification.

Market Differentiator CFT capabilities are positioned as pioneering and unique in ex vivo volumetric tissue imaging, with co-registered anatomical and molecular data and six-plex co-localization. Target large pharma, biotech, and CROs with preclinical imaging needs, early-stage drug delivery programs, and therapeutic protein studies.

Funding Momentum Recent financing activity signals growth potential and budget confidence for larger, multi-year imaging projects and collaborations. Leverage this momentum to engage enterprise customers by offering scalable service constructs, long-term access to Natick facilities, and preferred-rate instrumentation terms.

Geographic Capacity Headquartered in Natick with a manufacturing facility in Owings Mills, EMIT can support U.S.-based and international clients through direct services and remote collaborations. Position these capabilities to labs expanding preclinical imaging programs or seeking to outsource scale-up vs. building in-house facilities.

In-house Instrumentation Xerra instrumentation sold through EMIT provides an in-house imaging option to researchers, creating an upsell path alongside CFT services. Develop outreach to labs, CROs, and universities for instrument procurement, installation, training, and ongoing service packages, complemented by ongoing research engagements.